Renin Co-Crystallization to Speed Cardiovascular Drug Discovery
News Aug 17, 2005
Renin inhibitors are currently under development for the treatment of hypertension, chronic renal disease and congestive heart failure.
A protease produced in the kidneys, renin cleaves angiotensinogen which is ultimately converted to angiotensin II, bringing about sodium retention and an increase in blood pressure.
Inhibiting renin in hypertensive individuals may provide benefits over current therapies to reduce blood pressure, decrease salt retention and may protect organs sensitive to hypertension such as the kidney, heart and brain.
ActiveSight's "ready-to-go" Portfolio Protein crystals are designed to allow pharmaceutical and biotech companies to take advantage of protein structure based drug design in their drug development programs, even if they do not have internal structural biology capabilities.
ActiveSight have said that clients can submit their lead compounds to it where they are co-crystallized with the Portfolio Protein of interest and the structure of the complex is solved, providing important, rapid lead development data to the client.
ActiveSight is employing crystallographic-grade recombinant human renin supplied by Proteos, Inc.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018